Circulating exosomal microRNAs as emerging non‐invasive clinical biomarkers in heart failure: Mega bio‐roles of a nano bio‐particle. Issue 12 (14th October 2020)

• Record Type: Journal Article
• Authors: Zhou, Runfa; Wang, Leiyan; Zhao, Gang; Chen, Dan; Song, Xiaoning; Momtazi‐Borojeni, Amir A.; Yuan, Haitao
• Is Part Of: IUBMB life. Volume 72:Issue 12(2020)
• Page Start: 2546
• Page End: 2562
• Publication Date: 2020-10-14
• Subjects: biomarker -- diagnosis -- exosome -- heart failure -- microRNA -- prognosis; Biochemistry -- Periodicals; Molecular biology -- Periodicals; 572.8
• DOI: 10.1002/iub.2396
• Languages: English
• ISSNs: 1521-6543

Abstract

Abstract: Exosomes are nano‐sized extracellular vesicles containing a cell‐specific biologically active cargo of proteins and genetic materials. Exosomes are constitutively released from almost all cell‐types and affect neighboring or distant cells through a complex intercellular exchange of the genetic information and/or regulation of certain gene expressions that change the function and behavior of recipient cells. Those released into body fluids are the major mediators of intercellular communications. The success of the biological functions of exosomes is highly mediated by the effective transfer of microRNAs (miRs). Exosomes secreted by a damaged or diseased heart can exhibit alterations in the miRs' profile that may reflect the cellular origin and (patho)physiological state, as a "signature" or "fingerprint" of the donor cell. It has been shown that the transportation of cardiac‐specific miRs in exosomes can be rapidly detected and measured, holding great potential as biomarkers in heart diseases. Currently, the search for new biomarkers of heart diseases remains a large and increasing enterprise. Notably, circulating exosomal miRs (Exo‐miRs) have successfully gained huge interests for their diagnostic and prognostic potentials. The present review highlights circulating Exo‐miRs explored for diagnosis/prognosis and outcome prediction in patients with heart failure (HF). To this end, we explain the feasibility of exosomes as clinical biomarkers, discuss the priority of circulating Exo‐miRs over non‐exosomal ones as a biomarker, and then outline reported circulating Exo‐miRs having the biomarker function in HF patients, together with their mechanism of action. In conclusion, circulating Exo‐miRs represent emerging diagnostic (Exo‐miR‐92b‐5p, Exo‐miR‐146a, Exo‐miR‐181c, and Exo‐miR‐495) and prognostic (Exo‐miR‐192, Exo‐miR‐194, Exo‐miR‐34a, Exo‐miR‐425, Exo‐miR‐744) biomarkers for HF.